The VPS24 antibody is a research tool used to detect VPS24 (Vacuolar Protein Sorting 24), a component of the Endosomal Sorting Complex Required for Transport (ESCRT) machinery, specifically the ESCRT-III subcomplex. VPS24. also known as CHMP3 (Charged Multivesicular Body Protein 3), plays a critical role in membrane remodeling processes, including multivesicular body (MVB) formation, cytokinesis, and viral budding. It facilitates the sorting of ubiquitinated cargo proteins into intraluminal vesicles of MVBs, which is essential for lysosomal degradation, receptor downregulation, and exosome biogenesis.
Antibodies targeting VPS24 are widely employed in studies investigating ESCRT-III dynamics, membrane scission mechanisms, and diseases linked to ESCRT dysfunction, such as cancer, neurodegenerative disorders, and viral infections (e.g., HIV-1 budding). These antibodies are typically validated in applications like Western blotting, immunofluorescence, and immunoprecipitation, often using cell lines or tissues with modulated ESCRT-III expression. Researchers also utilize VPS24 antibodies to explore its interaction with other ESCRT components (e.g., CHMP2. VPS4 ATPase) and its role in cellular stress responses or apoptosis. Commercial VPS24 antibodies are often raised against recombinant protein fragments or synthetic peptides, with specificity confirmed via knockout validation. Its study contributes to understanding membrane trafficking pathologies and therapeutic targeting of ESCRT-related pathways.